Embecta Corp. (EMBC)
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
- Symbol
- EMBC
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $316.16M
- 52 week range
- 2.77 - 14.91
Valuation
- Share price
- $5.58 (close of 2026-09-23)
- P/E (TTM)
- 3.72x
- Price to book
- -0.52x
- Price to free cash flow
- 1.92x
- Enterprise value
- $1.59B
- Book value per share
- $-10.81
Price performance
| Period | Change |
|---|
| 1 day | +5.28% |
| 5 days | +9.63% |
| 1 month | +6.69% |
| 3 months | +78.27% |
| 6 months | -38.21% |
| Year to date | -53.03% |
| 1 year | -61.70% |
| 3 years | -63.21% |
| All time | -88.13% |
Profitability and growth
- Return on equity
- -14.66%
- Return on invested capital
- 36.30%
- Return on assets
- 8.75%
- Return on capital employed
- 29.19%
- Gross margin
- 62.64%
- Net margin
- 8.83%
- EBITDA margin
- 26.18%
- Revenue growth
- -3.80%
- Net income growth
- 21.84%
- Free cash flow growth
- 816.58%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 52.06%
- Current ratio
- 1.68x
- Net debt to EBITDA
- 4.78x
Latest reported year
- Period end
- 2025-09-30
- Fiscal year
- 2025
- Revenue
- $1.08B
- Cost of revenue
- $403.60M
- Gross profit
- $676.80M
- EBITDA
- $282.80M
- Net income
- $95.40M
- Earnings per share
- $1.64
- Research and development
- $37.30M
- Shares outstanding
- 58.31M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-09-30 | $1.08B | $676.80M | $95.40M | $1.64 |
| 2024-09-30 | $1.12B | $735.20M | $78.30M | $1.36 |
| 2023-09-30 | $1.12B | $749.90M | $70.40M | $1.23 |
| 2022-09-30 | $1.13B | $774.90M | $223.60M | $3.92 |
| 2021-09-30 | $1.17B | $800.40M | $414.80M | $7.28 |
| 2020-09-30 | $1.09B | $762.60M | $427.60M | $7.50 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-09-30 | 62.64% | 8.83% | -14.66% | 36.30% |
| 2024-09-30 | 65.46% | 6.97% | -10.61% | 27.68% |
| 2023-09-30 | 66.91% | 6.28% | -8.57% | 37.96% |
| 2022-09-30 | 68.61% | 19.80% | -25.08% | 65.62% |
| 2021-09-30 | 68.69% | 35.60% | 69.80% | 68.83% |
| 2020-09-30 | 70.25% | 39.39% | 74.73% | 74.85% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-09-30 | $225.50M | $1.39B |
| 2024-09-30 | $267.50M | $1.57B |
| 2023-09-30 | $326.30M | $1.59B |
| 2022-09-30 | $330.90M | $1.60B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-09-30 | $182.40M | $31.60M |
| 2024-09-30 | $19.90M | $26.30M |
| 2023-09-30 | $41.20M | $21.50M |
| 2022-09-30 | $388.60M | $18.70M |
| 2021-09-30 | $419.50M | $12.80M |
| 2020-09-30 | $456.60M | $12.70M |
Dividend history
- Most recent payment
- 2026-08-27
- Paid in the last twelve months
- $0.32
| Payment date | Dividend per share |
|---|
| 2026-08-27 | $0.01 |
| 2026-05-28 | $0.01 |
| 2026-02-27 | $0.15 |
| 2025-12-05 | $0.15 |
| 2025-08-29 | $0.15 |
| 2025-05-28 | $0.15 |
| 2025-02-28 | $0.15 |
| 2024-12-06 | $0.15 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-07 | Jun/2026 | $0.26 |
| 2026-05-05 | - | - |
| 2026-02-05 | - | - |
| 2025-11-25 | - | - |
| 2025-08-08 | - | - |
| 2025-05-09 | - | - |
| 2025-02-07 | - | - |
| 2025-02-06 | - | - |
Filings and sources
- Company website
- embecta.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades